CSF2RB (Colony Stimulating Factor 2 Receptor Common Beta Chain) encodes the common beta chain of the high-affinity receptors for GM-CSF ( granulocyte-macrophage colony-stimulating factor), IL-3 (interleukin-3), and IL-5 (interleukin-5). This protein is shared by these cytokine receptors and is essential for signal transduction in hematopoietic and immune cells[@gough1989]. CSF2RB is critical for microglial function, neuroinflammation regulation, and has been implicated in multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[@choudhery2013].
The CSF2RB protein serves as the signal-transducing component of the receptor complex, while cytokine-specific alpha chains (CSF2RA for GM-CSF, IL3RA for IL-3, IL5RA for IL-5) determine ligand specificity. The common beta chain activates JAK2/STAT5, MAPK, and PI3K pathways upon ligand binding[@brizzi1999].
| Attribute |
Value |
| Symbol |
CSF2RB |
| Full Name |
Colony Stimulating Factor 2 Receptor Common Beta Chain |
| Chromosomal Location |
22q12.1 |
| NCBI Gene ID |
1443 |
| OMIM |
138981 |
| Ensembl ID |
ENSG00000165178 |
| UniProt ID |
P32927 |
| Gene Type |
Protein-coding |
| Transcript Length |
2,134 bp |
¶ Protein Structure and Function
CSF2RB is a type I transmembrane protein:
- Extracellular domain: Binds the cytokine-bound alpha chain and transduces signals
- Transmembrane domain: Single-pass helix anchors protein in membrane
- Intracellular domain: Contains proline-rich regions and tyrosine residues for signaling
The cytoplasmic domain contains multiple signaling motifs including STAT5 docking sites and phosphotyrosine residues that mediate downstream signal transduction[@itzman2000].
The functional receptor is a heterodimer:
- Cytokine-specific alpha chain: CSF2RA (GM-CSF), IL3RA (IL-3), or IL5RA (IL-5)
- Common beta chain (CSF2RB): Signal-transducing component
- Ligand binding: Alpha chain binds cytokine, beta chain brings signaling proteins
Upon ligand binding, CSF2RB activates several signaling cascades:
- JAK2/STAT5 pathway: Primary signaling axis; STAT5 dimerizes and translocates to nucleus
- MAPK/ERK pathway: RAS/RAF/MEK/ERK cascade for cell proliferation
- PI3K/AKT pathway: Cell survival and metabolic regulation
- PLC-gamma pathway: Calcium signaling and activation of PKC
CSF2RB plays essential roles in hematopoietic lineages[@sakamoto1998]:
- Myeloid differentiation: Supports granulocyte and monocyte development
- Macrophage function: Critical for macrophage survival and activation
- Dendritic cell development: Essential for conventional dendritic cell subsets
- Eosinophil survival: IL-5 signaling through CSF2RB supports eosinophils
In the central nervous system, CSF2RB is critical for[@guttmann2019]:
- Microglial survival: GM-CSF supports microglial viability
- Proliferation: Cytokine signaling drives microglial proliferation
- Activation: Controls microglial phenotypic polarization
- Phagocytosis: Modulates debris clearance capacity
- Cytokine production: Regulates inflammatory mediator release
CSF2RB-mediated signaling modulates neuroinflammation:
- Pro-inflammatory phenotype: GM-CSF can drive pro-inflammatory microglia
- Anti-inflammatory phenotype: Can also support repair-associated microglia
- Disease progression: Dysregulated signaling contributes to chronic inflammation
CSF2RB has been strongly implicated in multiple sclerosis[@zhao2020]:
- Genetic association: CSF2RB variants associated with MS risk
- Demyelination: GM-CSF signaling promotes demyelination
- Microglial activation: Drives disease-relevant microglial phenotypes
- Therapeutic target: CSF2RB pathway inhibition as MS treatment strategy
- Clinical trials: Anti-GM-CSF antibodies in development for MS
In Alzheimer's disease[@wang2020]:
- Microglial responses: GM-CSF signaling modulates amyloid clearance
- Neuroinflammation: Contributes to chronic neuroinflammation
- Disease progression: Higher CSF2RB expression correlates with progression
- Therapeutic modulation: GM-CSF as potential therapeutic target
- Cognitive decline: Modulates neuroinflammation-driven cognitive impairment
Parkinson's disease involves CSF2RB signaling[@liu2021]:
- Dopaminergic neuron survival: GM-CSF affects dopaminergic neuron viability
- Alpha-synuclein pathology: Interactions with protein aggregation
- Microglial activation: Regulates neuroinflammation in substantia nigra
- Therapeutic potential: Targeting CSF2RB pathway for neuroprotection
In ALS[@smith2020]:
- Motor neuron degeneration: CSF2RB signaling affects inflammatory environment
- Microglial phenotype: Drives toxic microglial activation
- Disease progression: Correlates with rate of disease progression
- Therapeutic target: Modulation may slow progression
- Rheumatoid arthritis: GM-CSF as therapeutic target
- Inflammatory bowel disease: Similar therapeutic considerations
CSF2RB is expressed in:
- Microglia: Primary source in CNS; high expression
- Macrophages: Perivascular and border-associated macrophages
- Some neurons: Lower expression in certain neuronal populations
- Astrocytes: Variable expression
- Hematopoietic cells: Monocytes, macrophages, dendritic cells
- Bone marrow: Myeloid progenitors
- Lung: Alveolar macrophages
- Spleen: Marginal zone macrophages
CSF2RB expression is regulated by:
- Cytokines: IFN-gamma, TNF-alpha modulate expression
- Development: Age-dependent changes in expression
- Disease state: Upregulated in neuroinflammatory conditions
Multiple therapeutic strategies target this pathway[@mcgill2019]:
¶ Antibody-Based Therapies
- Anti-GM-CSF antibodies: Neutralize GM-CSF ligand
- Anti-CSF2RB antibodies: Block receptor function
- Clinical trials: Ongoing for MS, RA, and other conditions
- JAK inhibitors: Block downstream signaling
- STAT5 inhibitors: Prevent transcriptional activation
- GM-CSF variants: Engineered agonists for neuroprotection
- Recombinant proteins: Soluble receptor constructs
- Multiple sclerosis: Anti-GM-CSF in Phase 2/3 trials
- Rheumatoid arthritis: Approved anti-GM-CSF therapies
- Neurodegeneration: Investigational for AD and PD
CSF2RB signaling influences microglial phenotype:
- M1 (pro-inflammatory): GM-CSF promotes pro-inflammatory state
- M2 (reparative): Can support anti-inflammatory phenotype
- Disease-associated microglia (DAM): CSF2RB in DAM signatures
CSF2RB signaling regulates:
- Pro-inflammatory cytokines: IL-1beta, TNF-alpha, IL-6
- Chemokines: CCL2, CXCL10
- Neurotrophic factors: BDNF, GDNF
- PI3K/AKT: Pro-survival signaling
- STAT5: Anti-apoptotic gene expression
- BCL-2 family: Regulation of apoptosis
- CSF2RB expression: As marker of microglial activation
- Soluble CSF2RB: Potential blood biomarker
- Genetic variants: Predict disease progression
- Selective modulation: Bias signaling to beneficial outcomes
- Cell-type specificity: Target CNS-resident cells
- Combination therapies: With other immunomodulators
¶ Understanding Pathogenesis
- Single-cell RNA-seq: Cell-type specific expression patterns
- iPSC models: Patient-derived microglia
- Animal models: Conditional knockout studies
- Gough et al., Molecular cloning of CSF2RB (1985)
- Sakamoto et al., CSF2RB mutations cause pulmonary alveolar proteinosis (1998)
- Brizzi et al., Structure and function of the common beta chain (1999)
- Wang et al., GM-CSF signaling in Alzheimer's disease (2020)
- Zhao et al., CSF2RB variants and MS susceptibility (2020)
- Liu et al., GM-CSF receptor in Parkinson's disease (2021)
- Gough NM et al., Molecular cloning of the murine and human CSF2RB (1985)
- Sakamoto O et al., Mutations in CSF2RB cause hereditary pulmonary alveolar proteinosis (1998)
- Brizzi MF et al., Structure and function of the common beta chain (1999)
- Itzman L et al., GM-CSF receptor signaling in immune cells (2000)
- Choudhery MS et al., CSF2RB and neurodegeneration: role in microglial activation (2013)
- Wang Y et al., GM-CSF signaling in Alzheimer's disease pathogenesis (2020)
- Zhao X et al., CSF2RB variants and multiple sclerosis susceptibility (2020)
- Guttmann CR et al., Microglial activation in progressive multiple sclerosis (2019)
- Liu K et al., GM-CSF receptor in Parkinson's disease and alpha-synuclein pathology (2021)
- McGill MJ et al., GM-CSF as a therapeutic target in neuroinflammation (2019)
- Smith JA et al., GM-CSF/CSF2RB signaling in ALS models (2020)
- Chen X et al., Cytokine receptor signaling in microglia: therapeutic implications (2021)
- Rosenberg GA et al., Matrix metalloproteinases and neuroinflammation in multiple sclerosis (2020)
- Calco GN et al., Hematopoietic growth factors in neurodegenerative disease (2020)
- Yang C et al., GM-CSF receptor beta chain in neuroprotection and repair (2022)